Naveen Pemmaraju: My clinical and translational work at a special session of the International Society for Experimental Hematology 2024

Naveen Pemmaraju shared a post on LinkedIn:

“Wonderful to be able to present my clinical & translational work, alongside Dr Marina Konopleva’s pre-clinical /translational work on BH3mimetics, BCL2, BCLxL at a special session of the ISEH – International Society for Experimental Hematology 2024 meeting this AM!
Special thanks to Caner Saygin for organizing and hosting us!

(L->R) Naveen Pemmaraju,, Dr Justin Taylor, Dr Anand Patel, Dr Marina Konopleva, Dr Ibrahim Aldoss.”

Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.